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Objectives: To compare treatment effectiveness in rheumatoid arthritis (RA) patients naïve to biological dis-
ease-modifying antirheumatic drugs (bDMARDs) treated with tocilizumab (TCZ) or TNF-inhibitor (TNFi) with
(-combo) or without (-mono) conventional synthetic DMARDs (csDMARDs).
Methods: Patients with RA across 7 European registries, naïve to bDMARDs who initiated treatment with TCZ
or TNFi from 2009 to 2016 were included. Drug retention rate was analyzed using KaplanMeier and Cox
models, and CDAI over time by mixed models. The proportions of patients reaching CDAI low disease activity
(LDA) and remission after one year were corrected for attrition.
Results: 6713 TNFi-combo, 3762 TNFi-mono, 646 TCZ-combo and 384 TCZ-mono were eligible. Crude median
retention was 3.67 years (95%CI 3.413.83) for TNFi-combo, 4.14 (3.774.62) for TNFi-mono, 2.98
(2.763.34) for TCZ-combo and 3.63 years (3.345.03) for TCZ-mono. After adjustment for covariates, coun-
try and year of treatment initiation stratiﬁcation, hazards of discontinuation were lower for TCZ-mono (0.60,
95% CI 0.520.69) and TCZ-combo (0.66, 95% CI 0.540.81) compared to TNFi-combo. Adjusted CDAI evolu-
tion was not signiﬁcantly different between groups. CDAI LDA and remission corrected for attrition were
similar between TCZ with or without csDMARDs and TNFi-combo.
Conclusion: In routine care across 7 European countries, the adjusted drug retention, adjusted CDAI over time
and attrition-corrected response proportion for RA patients were similar for bio-naïve patients if treated
with TNFi-combo, TCZ-combo or TCZ-mono.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Monotherapyc. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Introduction
Rheumatoid arthritis (RA) is a chronic and systemic autoimmune
disease which causes joint pain and inﬂammation, and can lead to joint
destruction, loss of function and decreased quality of life [1]. Early
treatment aiming to suppress or decrease disease activity can
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gets are not reached by conventional synthetic disease-modifying anti-
rheumatic drugs (csDMARDs), the current recommendations advocate
the addition of biologic disease-modifying antirheumatic drugs
(bDMARDs) or targeted synthetic disease-modifying antirheumatic
drugs (tsDMARDs) [2]. Tocilizumab (TCZ) is a humanized antibody tar-
geting the interleukin-6 receptor that has proven its effectiveness in
decreasing disease activity and thus inhibiting structural damage and
loss of function [3,4]. In the ADACTA randomized controlled trial,
TCZ as monotherapy was more effective than adalimumab as mono-
therapy [5]. In a real-world study of non-bio-naïve European RA
patients, the effectiveness of TCZ monotherapy and TCZ or TNF-
inhibitors (TNFi) in combination with csDMARDs were comparable [6].
Similar ﬁndings were reported in a study from the US CORRONA cohort
comparing TCZ as monotherapy to TNF-inhibitors in combination ther-
apy in patients with prior TNFi use [7]. In general, bio-naïve patients
have higher response rates to bDMARD therapy than patients with prior
bDMARD use [8,9]. However, to our knowledge, no study evaluated
effectiveness in a large number of bio-naïve patients receiving TCZ ther-
apy. Therefore, this study is aimed at comparing the effectiveness of TCZ
and TNFi as monotherapy or in combination with csDMARDs in patients
with no prior use of bDMARDs or tsDMARDs using a collaboration of
registries from several countries. Secondary objectives were to compare
TCZ as monotherapy to TNFi in combination therapy with different
types of csDMARDs and different dosage of methotrexate.
Methods
The TOcilizumab Collaboration of European Registries in RA
(TOCERRA) is an investigator-led, industry-supported, collaborative
initiative involving several European registries with longitudinal data
of RA patients initiating TCZ or TNFi which has been described else-
where [6,9]. Local ethical approval was obtained and informed con-
sent was given to the participants for each registry, and the Geneva
Ethics Committee approved the collaboration study. For this study,
only the registries that contributed with bDMARDs- and tsDMARDs-
naïve patients treated by TCZ or TNFi were included, thus comprising
7 registries: Czech Republic (ATTRA), Italy (GISEA), Norway (NOR-
DMARD), Portugal (Reuma.pt), Romania (RRBR), Slovenia (BioRx.si)
and Spain (BIOBADASER). Patients were eligible if they had a diagno-
sis of RA established by a rheumatologist, started treatment with TCZ
or a TNFi between January 1st, 2009 and March 15th, 2018, and have
not been previously treated by a bDMARD or tsDMARD.
Exposure of interest
The main exposure of interest was the type of bDMARDs (TNFi and
TCZ) with or without concomitant treatment with csDMARDs at base-
line, thus comprising 4 groups: TNFi-combo, TNFi-mono, TCZ-combo,
TCZ-mono.
As a secondary analysis, we compared the TCZ-mono group to the
TNFi-combo group across different types of concomitant csDMARDs
(MTX, MTX and at least one other csDMARD or at least one other
csDMARDwithout MTX) and, for TNFi-combowithMTX only, across dif-
ferent dosage of MTX (categorized as having low-dose (<10mg/week),
medium-dose (1015mg/week) and high-dose (>15mg/week)).
Study outcomes
Our main outcomes for assessing effectiveness consisted in three
parts: (1) drug retention, (2) evolution of disease activity in terms of
Clinical Disease Activity Index (CDAI) and (3) rates of CDAI remission
(CDAI 2.8) and low disease activity (LDA, CDAI  10) [10,11]. Evo-
lution of the Disease Activity Score-28 (DAS28), patient global
assessment (PGA), physician global assessment (PhGA) and rates of
DAS28 remission (DAS28 <2.6) [12,13] and LDA (DAS28 <3.2) werealso analyzed as secondary endpoints. bDMARD exposure was
deﬁned as the time from start date of treatment until the discontin-
uation date plus one month, as it was estimated that treatment
should still be effective during the following month on disease activ-
ity (CDAI and DAS28). The exposure was censored at date of the last
reported follow-up visit plus one month if treatment was not dis-
continued. We considered only the ﬁrst course of bDMARD treat-
ment. Indeed, if the patients switched to another bDMARD, he/she
was no longer considered bio-naïve.
For the third part on CDAI and DAS28 remission and LDA rates, out-
comes were analyzed at 1 year, as earlier evaluations were not feasible
considering the frequency of assessments in most of the registries.
Covariates
The baseline covariates considered were age, gender, seropositiv-
ity, route of delivery (subcutaneous vs intravenous), ever smoking,
use of glucocorticoids (GC), disease activity (CDAI and DAS28),
functional disability (Health Assessment Questionnaire Disability
Index, HAQ-DI), presence of comorbidities (cardiovascular disease,
interstitial lung disease, infection, malignancy and/or neuropsychiat-
ric disorder), year of treatment initiation and country of registry.
These covariates were assessed at baseline and not considered as
time-varying. Information on the level of education was missing in
60% of patients and was not used for adjustment. We deﬁned sero-
positivity as positive if RF or ACPA were positive, negative if both
were negative and missing if one was missing and the other was neg-
ative. When no observed values for CDAI, DAS28 and HAQ-DI within
a three-month window were available, they were imputed using a
quadratic polynomial interpolation for each patient.
Previous csDMARD use was not assessed, as most patients were
included in the registries only at the start of bDMARDs or tsDMARDs
and previous use of csDMARDs before their inclusion in the registries
was not well documented.
Statistical methods
Baseline characteristics
Baseline characteristics were compared using Chi-Squared test
for categorical variables and Wilcoxon Rank sum test for continuous
variables.
Analysis of drug retention
For the ﬁrst analysis about drug retention, we used KaplanMeier
and Cox models. Baseline hazards were allowed to vary by country of
registries and year of treatment initiation in the Cox models. Missing
covariates were imputed using multiple imputations with chained
equations, using 50 samples. The Cox models were adjusted for each
baseline covariates described in the Covariates section, except for cal-
endar year of treatment initiation and country of registry which were
used as stratiﬁcation terms and level of education, which was not
used considering its missingness.
Analysis of CDAI and DAS28 change over time
For the second analysis evaluating CDAI and DAS28 change over
time, mixed-effects models for longitudinal data with a cubic effect
of time were used. We did not include Spain into this analysis
because this registry records CDAI and DAS28 only at baseline,
excluding a total of 564 patients (312 TNFi-combo, 21 TNFi-mono,
195 TCZ-combo, 36 TCZ-mono). To assess whether the type of treat-
ment had different trajectories of CDAI over time, we used a model
with an interaction and another without and compared them using
Bayesian Information Criteria (BIC). This BIC is less sensitive to obtain-
ing signiﬁcant effect only due do large sample size. The mixed-effect
models were adjusted for each baseline covariates described in the
Covariates section, except level of education.
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For the third analysis evaluating one-year remission or LDA, crude
proportions of patients reaching clinical response were calculated
and compared with the Chi-Squared test. In addition, drug discontin-
uation was corrected using the LUNDEX index ([proportion of
patients achieving response criteria] x [proportion of patients still
adhering to therapy]) [14], combining clinical response and adher-
ence to therapy. The purpose is to avoid a selection bias in favor of
responders only when evaluating response, overestimating drug
effectiveness. We computed conﬁdence intervals around the differen-
ces in LUNDEX-corrected remission or LDA rates using bootstrap with
10,000 bootstrap samples. For the same reason as for the second anal-
ysis on CDAI and DAS28 change over time, we did not include the
Spanish registry.
Sensitivity analysis
As a sensitivity analysis, we analyzed all outcomes excluding Italy, as
Italy was the main contributor of bio-naïve patients, particularly as
monotherapy, providing more than half of TNFi and TCZ-mono patients.
Evaluation of model adequacy and statistical package
We veriﬁed the absence of collinearity by a variance inﬂation fac-
tor and the absence of interaction between treatment and country
before pooling the results.
We tested the validity of the Coxmodel regarding the assumptions of
proportional hazards, linearity and absence of inﬂuential observations.
All analyses and tabulations were performed using R V.3.4.2 with
the mice, car, survival, lme4 and lmertest packages.
Results
Baseline characteristics
A total of 11,505 patients were retrieved before March 15th, 2018,
including 6713 TNFi-combo, 3762 TNFi-mono, 646 TCZ-combo and
384 TCZ-mono patients at baseline (Table 1). Missing values are pre-
sented in Supplementary Table S1. All registries contributed to the
four groups.Table 1
Baseline characteristics
N = 11,505 TNFi-combo n = 6713
Total number of visits (median [IQR]) 4 [28]
Total patient-years 14,924.8
Age, yr (median [IQR]) 54.9 [45.4, 62.7]
Female gender, n (%) 5265 (78.4)
Education category
010 years 1222 (32.3)
1113 years 1955 (51.6)
>13 years 610 (16.1)
Ever smoker 1630 (36.6)
Comorbidity 2888 (64.2)
Disease duration, yrs (median [IQR]) 6.7 [2.4, 12.2]
Seropositivity (RF and/or ACPA), n (%)) 3597 (79.4)
Glucocorticoids 3634 (69.9)
Glucocorticoid dose, mg/day (median, IQR) 5.0 [5.0, 8.0]
Route of delivery (subcutaneous) 4444 (88.4)
DAS28 (median [IQR]) 5.2 [4.1, 6.2]
CDAI (median, [IQR]) 20.8 [15.0, 34.0]
HAQ-DI (median, [IQR]) 1.1 [1.0, 1.6]
TJC (over 28 joints) (median, [IQR]) 9.0 [4.0, 14.0]
SJC (over 28 joints) (median, [IQR]) 6.0 [2.0, 10.0]
PGA (median, [IQR]) 60.0 [40.0, 80.0]
PhGA (median, [IQR]) 50.0 [30.0, 70.0]
ESR (mm/hour) (median, [IQR]) 27.0 [15.0, 42.0]
CRP (mg/L) (median, [IQR]) 7.0 [2.0, 19.7]
ACPA: anti-citrullinated peptide antibody; CDAI: Clinical Disease Activity Index; combo: in co
Disease Activity Score 28; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment
patient global assessment; PhGA: Physician global assessment; RF: rheumatoid factor; SJC: swoPatients with TCZ were older, with longer disease duration. Route
of delivery was mostly subcutaneous for TNFi patients and intrave-
nous for TCZ patients. Patients in monotherapy were younger, had
longer disease duration, less frequently used glucocorticoids at base-
line and were more often smokers. Patients with TNFi-combo had the
most severe disease characteristics at baseline (higher DAS28, CDAI,
HAQ-DI, TJC, ESR and CRP). TNFi-mono had the least severe disease
characteristics at baseline and were younger.
The baseline characteristics of the patients included in the sensi-
tivity analysis excluding Italy are presented in the Supplementary
Table S2, and details of patients with TNFi-combo and different types
of csDMARDs or doses of MTX are presented in Supplementary Table
S3 and S4.Survival analyses
A total of 2864 TNFi-combo, 1200 TNFi-mono, 334 TCZ-combo and
121 TCZ-mono stopped treatment during follow-up. Crude median
retention was 3.67 years (95% CI 3.413.83) for TNFi-combo,
4.14 years (3.774.62) for TNFi-mono, 2.98 years (2.763.34) for
TCZ-combo, 3.63 years (3.345.03) for TCZ-mono.
After adjustment for covariates and stratiﬁcation by country and
year of treatment initiation, we found that, compared to TNFi-
combo, hazards of discontinuation were higher for TNFi-mono (HR:
1.24, 95% CI 1.131.36, Table 2) and lower for TCZ-mono (0.60,
0.520.69) and TCZ-combo (0.66, 0.540.81). There was no statisti-
cally signiﬁcant difference in hazards of discontinuation for TCZ-
mono compared to TCZ-combo (1.10, 0.881.37). Female gender,
younger age, shorter disease duration, presence of a comorbidity at
baseline, smoking, use of glucocorticoids at baseline, intravenous
delivery, higher HAQ-DI and DAS28 were associated with a higher
risk of discontinuation.
Results were similar in the sensitivity analysis excluding the Ital-
ian registry.
For the subanalysis of TCZ vs TNFi patients with different types of
csDMARDs, crude median retention among TNFi-combo patients
with any type of csDMARDs was lower than for TCZ patients
(p < 0.001, Supplementary Figure S1, panel A). Adjusted hazards ofTNFi-mono n = 3762 TCZ-combo n = 646 TCZ-mono n = 384
3 [37] 2 [18] 2 [36]
6728.7 1511.7 676.0
52.0 [41.4, 61.3] 56.1 [46.2, 63.5] 54.8 [46.5, 64.5]
2434 (64.7) 520 (80.5) 317 (82.6)
143 (31.3) 113 (44.8) 23 (31.1)
225 (49.2) 104 (41.3) 40 (54.1)
89 (19.5) 35 (13.9) 11 (14.9)
987 (38.2) 138 (30.3) 96 (36.8)
1375 (70.8) 294 (57.0) 136 (62.4)
9.7 [6.6, 15.1] 7.4 [3.5, 12.3] 10.0 [6.3, 16.4]
659 (71.0) 371 (82.4) 134 (81.7)
532 (60.0) 391 (72.8) 84 (48.6)
5.0 [4.0, 8.0] 5.0 [5.0, 10.0] 5.0 [4.0, 7.5]
649 (91.3) 184 (36.4) 58 (37.4)
4.1 [3.7, 5.4] 4.7 [3.7, 6.2] 4.7 [4.1, 6.0]
17.6 [15.0, 23.0] 17.6 [17.6, 30.0] 17.6 [17.6, 30.0]
1.0 [0.8, 1.3] 1.0 [1.0, 1.7] 1.0 [1.0, 1.6]
5.0 [1.0, 11.0] 8.0 [3.0, 14.0] 7.0 [4.0, 12.0]
3.0 [0.0, 8.0] 6.0 [2.0, 10.0] 5.0 [2.0, 9.0]
60.0 [42.0, 80.0] 66.0 [41.2, 80.0] 62.0 [50.0, 80.0]
50.0 [30.0, 70.0] 50.0 [34.2, 70.0] 50.0 [40.0, 70.0]
22.0 [11.0, 38.0] 26.0 [10.0, 46.0] 26.5 [10.8, 48.2]
1.6 [0.5, 5.1] 6.2 [1.1, 19.0] 2.1 [0.6, 9.0]
mbination with conventional synthetic disease-modifying antirheumatic drugs; DAS28:
Questionnaire Disability Index; IQR: interquartile range; mono: as monotherapy; PGA:
llen joint counts; TCZ: tocilizumab; TJC: tender joint counts; TNFi: TNF inhibitor.
Table 2
Multivariable analysis of drug discontinuation
HR 95%CI p
TNFi-combo (comparator)   
TNFi-mono 1.24 1.131.36 <0.001
TCZ-mono 0.60 0.520.69 <0.001
TCZ-combo 0.66 0.540.81 <0.001
Age, yr 1.00 0.991.00 0.03
Female gender 1.21 1.121.30 <0.001
Body Mass Index 1.00 0.991.01 0.85
Ever smoking 1.12 1.021.24 0.02
Comorbidity 1.13 1.041.23 0.003
Disease duration, yr 0.99 0.991.00 0.02
Seropositivity 1.00 0.911.11 0.92
Subcutaneous delivery 0.70 0.640.77 <0.001
Glucocorticoids 1.27 1.141.40 <0.001
HAQ-DI at baseline 1.09 1.051.13 <0.001
CDAI at baseline 1.00 1.001.00 0.69
DAS28 at baseline 1.16 1.121.20 <0.001
CDAI: Clinical Disease Activity Index; combo: in combination with conventional syn-
thetic disease-modifying antirheumatic drug, DAS28: Disease Activity Score-28; HAQ-
DI: Health Assessment Questionnaire Disability Index; mono: as monotherapy; TCZ:
tocilizumab; TNFi: TNF-inhibitor.
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comitants csDMARDs than TCZ-mono.
Among TNFi-combo patients with MTX only (n = 3972), crude
median drug retention was lower but not statistically signiﬁcantly
different compared to TCZ-mono (p = 0.138, Supplementary Fig. S1,
panel B). Adjusted hazards of discontinuation were higher for TNFi-
combo with any dosage of MTX than TCZ-mono.
The Cox models were valid regarding the assumptions of propor-
tional hazards, linearity and absence of inﬂuential observations.Fig. 1. Unadjusted KaplanMeier cEvolution of CDAI and DAS28 over time
In all groups, CDAI score decreased rapidly during the ﬁrst 2 years
(Fig. 2). After adjustment, the CDAI evolution was not signiﬁcantly dif-
ferent between groups (lower BIC in the model without interaction
between time and treatment group), although there was some differ-
ence in the average CDAI at any time during follow-up, which was
higher in TNFi-mono, and lower with TCZ-combo (Table 3). Presence of
comorbidity, glucocorticoids, higher HAQ-DI and CDAI at baseline were
associated with higher CDAI at any time during follow-up. Results were
similar in the sensitivity analysis excluding the Italian patients.
DAS28 evolution was similar between groups, however average
DAS28 at any point during follow-up was lower in the TCZ-mono and
TCZ-combo groups and higher for the TNFi-mono group compared to
TNFi-combo. PGA and PhGA evolution were also not signiﬁcantly dif-
ferent between groups.
CDAI evolution was not signiﬁcantly different for TNFi-combo
across any type of concomitant csDMARDs or doses of MTX compared
to TCZ-mono.CDAI and DAS28 LDA and remission at 1 yearCrude analysis
A total of 4074 TNFi-combo, 2086 TNFi-mono, 286 TCZ-combo and
203 TCZ-mono were still under the same treatment at one year, with
respectively 17.7%, 17.6%, 18.2% and 16.6% in CDAI remission (p = 0.97)
and 72.9%, 79.0%, 73.4% and 68.5% in CDAI LDA (p < 0.001). For DAS28,
there were 36.1%, 33.5%, 64.4%, 54.3% (p < 0.001) in remission and
61.0%, 71.1%, 82.2% and 75.8% (p< 0.001) in LDA, respectively.urves of drug discontinuation.
Fig. 2. Multivariable analysis of Clinical Disease Activity Index (CDAI) over time modeled with a cubic effect of time and adjusted for age, gender, disease duration, seropositivity,
presence of glucocorticoids, route of delivery (subcutaneous or intravenous), smoking, Health Assessment Questionnaire Disability Index score, Clinical Disease Activity Index, Dis-
ease Activity Score 28 and presence of a comorbidity at baseline. TNFi-combo, TNF inhibitor in combination with csDMARDs; TNFi-mono, TNF inhibitor as monotherapy; TCZ-
combo, tocilizumab in combination with csDMARDs; TCZ-mono, tocilizumab as monotherapy.
Table 3
Multivariable analysis of CDAI over time
Overall
coeff 95%CI p
Treatment at baseline
TNFi-combo (comparator)   
TNFi-mono 1.13 0.321.94 0.006
TCZ-combo 2.08 3.250.91 <0.001
TCZ-mono 0.29 1.612.18 0.77
Time, yr 16.19 16.7115.68 <0.001
Age, yr 0.02 0.040.01 0.17
Female gender 0.40 0.271.06 0.24
BMI 0.03 0.020.08 0.27
Comorbidities 0.39 0.170.95 0.17
Smoking 1.03 0.371.69 0.002
Disease duration, yr 0.02 0.060.02 0.28
Seropositivity 0.39 1.120.33 0.28
Route of bDMARDs delivery (subcutaneous) 0.35 1.120.42 0.37
Glucocorticoids 1.01 0.471.54 <0.001
HAQ-DI at baseline 1.70 1.272.13 <0.001
CDAI at baseline 0.36 0.320.40 <0.001
DAS28 at baseline 0.12 0.510.27 0.55
CDAI: Clinical Disease Activity Index; combo: in combination with conventional
synthetic disease-modifying antirheumatic drug DAS28: Disease Activity Score 28,
HAQ-DI: Health Assessment Questionnaire Disability Index; mono: as monotherapy;
TCZ: tocilizumab, TNFi: TNF inhibitor.
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After LUNDEX correction for attrition, CDAI remission and LDA
rates were similar, except for slightly higher rates of CDAI LDA in the
TNFi-mono group (Fig. 3). LUNDEX-corrected DAS28 remission rates
and LDA were higher in the TCZ-mono and TCZ-combo groups than
the TNFi-mono and TNFi-combo groups.
In the sensitivity analysis excluding Italian patients, the rates of
LUNDEX-corrected CDAI remission were lower in the TNFi-mono
(9.0%, Supplementary Figure S4) and TCZ-mono (10.2%) groups than
the TNFi-combo (13.1%) and TCZ-combo (14.7%) groups. This differ-
ence was statistically signiﬁcant for the TNFi-mono group but not the
TCZ-mono group compared to TNFi-combo. LUNDEX-corrected CDAI
LDA rates were similar between groups.When comparing TNFi with different type of csDMARDs and dos-
age of MTX (Supplementary Fig. S2 and S3) and TCZ-mono, there
were no signiﬁcant differences except for TCZ-mono vs TNFi with
high dose of MTX favoring TCZ-mono.Discussion
Using data from the TOCERRA collaboration, we evaluated the effec-
tiveness of tocilizumab and TNF-inhibitors with and without concomi-
tant csDMARDs in patients naïve to bDMARDs and tsDMARDs. We
found that, after adjustment for confounding factors, drug retention was
higher in TCZ, whether as monotherapy or in combination therapy, than
TNFi in combination therapy, and lower with TNFi as monotherapy.
CDAI evolution was not different between groups, after adjust-
ment for confounders, although average CDAI at any time during
follow-up was higher with TNFi-mono and lower for TCZ-combo.
Proportions of CDAI remission and LDA activity were similar in the
main analysis, except for a slightly higher rate of LUNDEX-corrected
CDAI remission in TNFi-mono patients. In the sensitivity analysis,
patients with TNFi-mono and TCZ-mono seemed to have slightly
lower proportion of remission, which was statistically signiﬁcant for
TNFi-mono but not TCZ-mono. These differences in results between
the two analyses may be explained by important differences in
patient and disease characteristics at baseline as the LUNDEX corrects
for attrition but not for baseline characteristics, year of treatment ini-
tiation or country. In particular, TNFi-mono patients, mainly owing to
patients from the Italian registry, had already the lowest disease
activity values according to several parameters (DAS28, CDA, CRP,
ESR and PGA) than the other groups at baseline. Thus, a higher pro-
portion of CDAI remission in TNFi-mono patients at one year is not
unexpected. Overall, it also raises the question on how to account for
bias and confounders in observational studies and how to interpret
their results. To limit the effect of confounding and in particular con-
founding by indication, we adjusted our analyses for several covari-
ates except when using the LUNDEX, which allow an adjustment for
attrition, but does not allow adjustment for covariates.
This study also shows that prescribing pattern may differ signiﬁ-
cantly from one country to another, as many patients were prescribed
TCZ-mono in Italy. However, we found no signiﬁcant interaction
Fig. 3. LUNDEX corrected Clinical Disease Activity Index (CDAI) and Disease Activity Score-28 (DAS28) remission and low disease activity (LDA) at 1 year. TNFi-combo, TNF inhibitor
in combination with csDMARDs; TNFi-mono, TNF inhibitor as monotherapy; TCZ-combo, tocilizumab in combination with csDMARDs; TCZ-mono, tocilizumab as monotherapy.
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the results.
We also found that smoking, glucocorticoid use, higher HAQ-DI
and higher CDAI at baseline were associated with higher CDAI at any
time during follow-up, which may be due to a more severe pattern of
disease.
Limitations of this study are partly inherent to its observational
design. Unmeasured confounders cannot be accounted for. We were
also unable to assess the previous use of csDMARDs as most patients
are included in the registries only at the start of bDMARD or
tsDMARD and previous use of csDMARDs before their inclusion in the
registries was not well documented. Yet, as in clinical practice,
bDMARDs and tsDMARDs are usually prescribed only after failing
csDMARDs, we do not believe that this would have substantially
changed the results. We also do not have details of the quality control
processes for each registry and data quality for each variables. Out-
comes may also be less precise than in a randomized controlled trial
as for example for disease activity, which may not be measured
exactly at one year and may have more missing data. As this initiative
was supported by the industry, we also could compare only tocilizu-
mab and TNF-inhibitors, as we did not have funding to analyze other
treatment groups. However, the observational nature also allows a
greater generalizability of the results, as patients were included with-
out the strict inclusion and exclusion criteria of randomized con-
trolled trials. The sample size was also large with a long duration of
follow-up and access to numerous covariates of interest. We also
used several parameters of effectiveness with different analytic meth-
ods yielding a valuable picture of the effectiveness of the different
treatment regimen tested.
We suggested in our previous study [6] that the longer retention
with TCZ could be linked to the absence of other alternative after
multiple bDMARDs failure. Comparable results were also found in a
study from the CORRONA RA registry [7], which also considered
bDMARD-experienced patients only. However, the presence of simi-
lar results in bio-naïve patients probably hints to other reasons forlonger drug maintenance with TCZ, as, for instance, better tolerability
or effectiveness. However, the exact reason for this could not be cap-
tured precisely in our study.
To our knowledge, no observational studies assessed the compar-
ative effectiveness of TCZ and TNFi with and without csDMARDs as a
ﬁrst-line therapy. In the ADACTA randomized clinical trial, the efﬁ-
cacy of TCZ was superior to adalimumab as monotherapy in bio-naïve
patients [5], and in the U-Act-Early trial of early arthritis, TCZ in com-
bination with csDMARDs did not perform better than as monother-
apy [15]. However, in the ACT-RAY study evaluating in csDMARD
inadequate responders a switch strategy to TCZ only or an add-on
strategy with TCZ and concomitant MTX, there were small differences
between the groups regarding radiographic progression, which
favored the add-on group [16].
Regarding the patient population, patients prescribed TCZ and
TNFi as monotherapy or in combination therapy differed in several
baseline characteristics. As in previous observational studies, focusing
on bDMARD-experienced patients, TCZ is used in older patients with
longer disease duration and patients treated as monotherapy less fre-
quently used glucocorticoids [6,7,17]. However, in contrast to
bDMARD-experienced patients where monotherapy was more fre-
quently prescribed to older patients [6,7,17], we did not ﬁnd a clear
pattern of prescription by age.
As in previous bDMARD studies, we found that female gender,
presence of a comorbidity, smoking, use of glucocorticoids, higher
HAQ-DI and DAS28 that may be linked to more difﬁcult to treat
patients were associated with a higher risk of drug discontinuation
[6,1820]. Patients treated as monotherapy (either TCZ or TNFi) had
lower CRP levels at baseline, as patients with lower doses of MTX,
suggesting that more aggressive treatment is prescribed to patients
with higher levels of inﬂammatory markers. Younger age and shorter
disease duration were also associated with higher discontinuation
rates in our study but this association has been inconsistently
described, with some studies pointing to higher discontinuation with
longer disease duration [20] and older age [18,21,22], or no effect
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ation rates, but it may be linked to a residual confounding of drugs or
could be linked to other factors that are not fully captured. In a previ-
ous study of this collaboration looking at retention in TCZ patients by
route of delivery, no difference was found in effectiveness between
the intravenous or subcutaneous route [24].
Altogether, in regard to higher rates of retention, similar CDAI
evolution and proportion of CDAI remission and LDA, our ﬁndings
suggest that TCZ-combo and TCZ-mono are suitable alternatives to
TNFi-combo. However, considering the lower rates of CDAI remission
in the sensitivity analysis, although not signiﬁcant for TCZ-mono, and
the results of the ACT-RAY study, whenever possible TCZ and TNFi
should be given in combination with csDMARDs. Yet, when
csDMARDs are not tolerated or contraindicated, TCZ seems to be a
more effective option than TNFi as monotherapy.
Conclusion
In conclusion, this real-world study shows that TCZ either as
monotherapy or in combination with csDMARDs is an adequate alter-
native to TNFi in combination with csDMARDs in bDMARDs and
tsDMARDs naïve patients and may be preferable over TNFi when
csDMARDs are contraindicated or not tolerated.
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